Sofinnova Partners hauled in $200 million in investment for its digital health fund as investors’ appetite for companies developing solutions for health care using digital technology continues to grow.

Triveni Bio Inc. has announced a $92 million series A financing that will support the advancement of its lead antibody program, TRIV-509, from preclinical development to a phase IIa clinical trial in atopic dermatitis and fuel a pipeline of novel antibodies with two additional development candidate nominations expected in 2024.

Emerging from stealth mode, Rampart Bioscience Inc. pulled down $85 million in series A money for work on DNA-based drugs – a round that was led by Forbion with participation from seed investor Orbimed and new backers RA Capital Management and Healthcap.

Phasev Inc. has raised $15 million in a funding round that will allow the company to further develop its machine learning (ML) technology that aims to revolutionize clinical trial design, execution and analysis. The funding round was led by Viola Ventures and Exor Ventures and included participation from Lionbird and a group of prominent angel investors.